Atypical psychological symptoms frequently occur in early-onset Alzheimer’s disease (EOAD), which makes it difficult to differentiate it from other psychiatric disorders. We report the case of a 28-year-old woman with EOAD, carrying a presenilin-1 mutation (S170P), who was initially misdiagnosed with schizophrenia because of prominent psychiatric symptoms in the first 1–2 years of the disease. Amyloid-β positron emission tomography (PET) showed remarkably high tracer uptake in the striatum and thalamus. Tau PET showed widespread cortical uptake and relatively low uptake in the subcortical and medial temporal regions. Our case advocates for considering EOAD diagnosis for young patients with psychiatric and atypical cognitive symptoms.
KoedamEL, LaufferV, van der VliesAE, van der FlierWM, ScheltensP, PijnenburgYA (2010) Early-versus late-onset Alzheimer’s disease: More than age alone. J Alzheimers Dis19, 1401–1408.
LleóA, BlesaR, QueraltR, EzquerraM, MolinuevoJL, Peña-CasanovaJ, RojoA, OlivaR (2002) Frequency of mutations in the presenilin and amyloid precursor protein genes in early-onset Alzheimer disease in Spain. Arch Neurol59, 1759–1763.
4.
JanssenJ, BeckJ, CampbellT, DickinsonA, FoxN, HarveyRJ, HouldenH, RossorM, CollingeJ (2003) Early onset familial Alzheimer’s disease: Mutation frequency in 31 families. Neurology60, 235–239.
5.
GerlachLB, KalesHC (2018) Managing behavioral and psychological symptoms of dementia. Psychiatr Clin North Am41, 127–139.
6.
BatemanRJ, AisenPS, De StrooperB, FoxNC, LemereCA, RingmanJM, SallowayS, SperlingRA, WindischM, XiongC (2011) Autosomal-dominant Alzheimer’s disease: A review and proposal for the prevention of Alzheimer’s disease. Alzheimers Res Ther3, 1.
7.
GolanMP, StyczyńskaM, JóźwiakK, WaleckiJ, MaruszakA, PniewskiJ, LugiewiczR, FilipekS, ZekanowskiC, BarcikowskaM (2007) Early-onset Alzheimer’s disease with a de novo mutation in the presenilin 1 gene. Exp Neurol208, 264–268.
8.
PortetF, DauvilliersY, CampionD, RauxG, HauwJJ, Lyon-CaenO, CamuW, TouchonJ (2003) Very early onset AD with a de novo mutation in the presenilin 1 gene (Met 233 Leu). Neurology61, 1136–1137.
9.
KaySR, FiszbeinA, OplerLA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull13, 261.
10.
PalmqvistS, ZetterbergH, BlennowK, VestbergS, AndreassonU, BrooksDJ, OweniusR, HägerströmD, WollmerP, MinthonL, HanssonO (2014) Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-amyloid 42: A cross-validation study against amyloid positron emission tomography. JAMA Neurol71, 1282–1289.
11.
SchöllM, OssenkoppeleR, StrandbergO, PalmqvistS; Swedish BioFINDER study, JögiJ, OhlssonT, SmithR, HanssonO (2017) Distinct 18F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimer’s disease. Brain140, 2286–2294.
12.
CarecchioM, PicilloM, VallettaL, EliaAE, HaackTB, CozzolinoA, VitaleA, GaravagliaB, IusoA, BagellaCF, PappatàS, BaroneP, ProkischH, RomitoL, TirantiV (2017) Rare causes of early-onset dystonia-parkinsonism with cognitive impairment: A de novo PSEN-1 mutation. Neurogenetics18, 175–178.
13.
RogaevaEA, FafelKC, SongYQ, MedeirosH, SatoC, LiangY, RichardE, RogaevEI, FrommeltP, SadovnickAD, MeschinoW, RockwoodK, BossMA, MayeuxR, St George-HyslopP (2001) Screening for PS1 mutations in a referral-based series of AD cases: 21 novel mutations. Neurology57, 621–625.
14.
LarnerAJ (2013) Presenilin-1 mutations in Alzheimer’s disease: An update on genotype-phenotype relationships. J Alzheimers Dis37, 653–659.
15.
RauxG, Guyant-MaréchalL, MartinC, BouJ, PenetC, BriceA, HannequinD, FrebourgT, CampionD (2005) Molecular diagnosis of autosomal dominant early onset Alzheimer’s disease: An update. J Med Genet42, 793–795.
16.
IkeuchiT, KanekoH, MiyashitaA, NozakiH, KasugaK, TsukieT, TsuchiyaM, ImamuraT, IshizuH, AokiK, IshikawaA, OnoderaO, KuwanoR, NishizawaM (2008) Mutational analysis in early-onset familial dementia in the Japanese population. The role of PSEN1 and MAPT R406W mutations. Dement Geriatr Cogn Disord26, 43–49.
17.
IrwinDJ, CohenTJ, GrossmanM, ArnoldSE, McCarty-WoodE, Van DeerlinVM, LeeVM, TrojanowskiJQ (2013) Acetylated tau neuropathology in sporadic and hereditary tauopathies. Am J Pathol183, 344–351.
18.
American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders. American Psychiatric Association, Washington, DC.
19.
JesteDV, FinkelSI (2000) Psychosis of Alzheimer’s disease and related dementias: Diagnostic criteria for a distinct syndrome. Am J Geriatr Psychiatry8, 29–34.
20.
BoraE, YücelM, PantelisC (2010) Cognitive impairment in schizophrenia and affective psychoses: Implications for DSM-V criteria and beyond. Schizophr Bull36, 36–42.
Santos-MandujanoRA, RyanNS, Chávez-GutiérrezL, Sánchez-TorresC, Meraz-RíosMA (2020) Clinical association of white matter hyperintensities localization in a Mexican family with spastic paraparesis carrying the PSEN1 A431E mutation. J Alzheimers Dis73, 1075–1083.
23.
MannDM, Pickering-BrownSM, TakeuchiA, IwatsuboT; Members of the Familial Alzheimer’s Disease Pathology Study Group (2001) Amyloid angiopathy and variability in amyloid beta deposition is determined by mutation position in presenilin-1-linked Alzheimer’s disease. Am J Pathol158, 2165–2175.
24.
LarnerAJ, DoranM (2006) Clinical phenotypic heterogeneity of Alzheimer’s disease associated with mutations of the presenilin-1 gene. J Neurol253, 139–158.
25.
LiuCY, OhkiY, TomitaT, OsawaS, ReedBR, JagustW, Van BerloV, JinLW, ChuiHC, CoppolaG, RingmanJM (2017) Two novel mutations in the first transmembrane domain of presenilin1 cause young-onset Alzheimer’s disease. J Alzheimers Dis58, 1035–1041.
26.
JohnsonEC, HoK, YuG-Q, DasM, SanchezPE, DjukicB, LopezI, YuX, GillM, ZhangW (2020) Behavioral and neural network abnormalities in human APP transgenic mice resemble those of App knock-in mice and are modulated by familial Alzheimer’s disease mutations but not by inhibition of BACE1. Mol Neurodegener15, 1–26.
27.
YanL, LiL, HanW, PanB, XueX, MeiB (2013) Age-related neuropsychiatric symptoms in presenilins conditional double knockout mice. Brain Res Bull97, 104–111.
28.
PughPL, RichardsonJC, BateST, UptonN, SunterD (2007) Non-cognitive behaviours in an APP/PS1 transgenic model of Alzheimer’s disease. Behav Brain Res178, 18–28.
29.
McCoolMF, VartyGB, Del VecchioRA, KazdobaTM, ParkerEM, HunterJC, HydeLA (2003) Increased auditory startle response and reduced prepulse inhibition of startle in transgenic mice expressing a double mutant form of amyloid precursor protein. Brain Res994, 99–106.
30.
HarrisJA, DevidzeN, HalabiskyB, LoI, ThwinMT, YuG-Q, BredesenDE, MasliahE, MuckeL (2010) Many neuronal and behavioral impairments in transgenic mouse models of Alzheimer’s disease are independent of caspase cleavage of the amyloid precursor protein. J Neurosci30, 372–381.
31.
HarrisJA, DevidzeN, VerretL, HoK, HalabiskyB, ThwinMT, KimD, HamtoP, LoI, YuG-Q (2010) Transsynaptic progression of amyloid-β-induced neuronal dysfunction within the entorhinal-hippocampal network. Neuron68, 428–441.
32.
SteinbergM, TschanzJT, CorcoranC, SteffensDC, NortonMC, LyketsosCG, BreitnerJC (2004) The persistence of neuropsychiatric symptoms in dementia: The Cache County Study. Int Geriatr Psychiatry19, 19–26.
33.
RingmanJM, LiangL-J, ZhouY, VangalaS, TengE, KremenS, WhartonD, GoateA, MarcusDS, FarlowM (2015) Early behavioural changes in familial Alzheimer’s disease in the Dominantly Inherited Alzheimer Network. Brain138, 1036–1045.
34.
TangM, RymanDC, McDadeE, JasielecMS, BucklesVD, CairnsNJ, FaganAM, GoateA, MarcusDS, XiongC (2016) Neurological manifestations of autosomal dominant familial Alzheimer’s disease: A comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS). Lancet Neurol15, 1317–1325.
35.
RyanNS, NicholasJM, WestonPS, LiangY, LashleyT, GuerreiroR, AdamsonG, KennyJ, BeckJ, Chavez-GutierrezL (2016) Clinical phenotype and genetic associations in autosomal dominant familial Alzheimer’s disease: A case series. Lancet Neurol15, 1326–1335.
36.
WongTH, SeelaarH, MelhemS, RozemullerAJ, van SwietenJC (2020) Genetic screening in early-onset Alzheimer’s disease identified three novel presenilin mutations. Neurobiol Aging86, 201.e209–201.e214.
37.
ZhangS, LiX, ZhangL, MengX, MaL, ZhangG, WuH, LiangL, CaoM, MeiF (2020) Identification of a rare PSEN1 mutation (Thr119Ile) in late-onset Alzheimer’s disease with early presentation of behavioral disturbance. Front Psychiatry11, 347.
38.
Ch’ngG-S, AnSSA, BaeSO, BagyinszkyE, KimS (2015) Identification of two novel mutations, PSEN1 E280K and PRNP G127S, in a Malaysian family. Neuropsychiatric Dis Treat11, 2315.
39.
LohmannE, GuerreiroRJ, Erginel-UnaltunaN, GurunlianN, BilgicB, GurvitH, HanagasiHA, LuuN, EmreM, SingletonA (2012) Identification of PSEN1 and PSEN2 gene mutations and variants in Turkish dementia patients. Neurobiol Aging33, 1850.e1817–1850.e1827.
40.
LiX, XiongZ, LiuY, YuanY, DengJ, XiangW, LiZ (2020) Case report of first-episode psychotic symptoms in a patient with early-onset Alzheimer’s disease. BMC Psychiatry20, 128.
QuirozYT, SperlingRA, NortonDJ, BaenaA, Arboleda-VelasquezJF, CosioD, SchultzA, LapointM, Guzman-VelezE, MillerJB (2018) Association between amyloid and tau accumulation in young adults with autosomal dominant Alzheimer disease. JAMA Neurol75, 548–556.
52.
SanchezJS, HanseeuwBJ, LoperaF, SperlingRA, BaenaA, BocanegraY, AguillonD, Guzmán-VélezE, Pardilla-DelgadoE, Ramirez-GomezL (2021) Longitudinal amyloid and tau accumulation in autosomal dominant Alzheimer’s disease: Findings from the Colombia-Boston (COLBOS) biomarker study. Alzheimers Res Ther13, 27.
53.
GordonBA, BlazeyTM, ChristensenJ, DincerA, FloresS, KeefeS, ChenC, SuY, McDadeEM, WangG (2019) Tau PET in autosomal dominant Alzheimer’s disease: Relationship with cognition, dementia and other biomarkers. Brain142, 1063–1076.
54.
FarberNB, RubinEH, NewcomerJW, KinscherfDA, MillerJP, MorrisJC, OlneyJW, McKeelDW (2000) Increased neocortical neurofibrillary tangle density in subjects with Alzheimer disease and psychosis. Arch Gen Psychiatry57, 1165–1173.
55.
MurrayPS, KirkwoodCM, GrayMC, FishKN, IkonomovicMD, HamiltonRL, KoflerJK, KlunkWE, LopezOL, SweetRA (2014) Hyperphosphorylated tau is elevated in Alzheimer’s disease with psychosis. J Alzheimers Dis39, 759–773.
